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We report the antimicrobial susceptibility patterns of the most frequently isolated Gram-positive bacteria in the
Brazilian hospitals participating in the SENTRY Antimicrobial Surveillance Program. The strains were consecutively
collected (one per patient) between January 2005 and September 2008 and susceptibility tested by reference broth
microdilution methods at the JMI Laboratories (North Liberty, Iowa, USA). A total of 3,907 Gram-positive cocci were
analyzed. The Gram-positive organisms most frequently isolated from bloodstream infections were Staphylococcus
aureus (2,218 strains; 20.2% of total), coagulase-negative staphylococci (CoNS; 812 strains [14.7%]), and Enterococcus
spp. (754 strains; 5.0%). S. aureus ranked first (28.1%) and Enterococcus faecalis ranked 7th (4.5%) among cases of
skin and soft tissue infections. S. aureus was also the second most frequently isolated pathogen from patients with
lower respiratory tract infections (24.9% of cases) after Pseudomonas aeruginosa (30.5%). Resistance to oxacillin was
observed in 31.0% of S. aureus and the vast majority of oxacillin-resistant (MRSA) strains were also resistant to
clindamycin, ciprofloxacin and levofloxacin. Vancomycin, linezolid and daptomycin were all very active against S.
aureus strains tested (>99.9-100.0% susceptible), but daptomycin (MIC50, 0.25 µg/mL and MIC90, 0.5 µg/mL) was
four- to eight-fold more potent than vancomycin (MIC50 and MIC90 of 1 µg/mL) and linezolid (MIC50, 1 µg/mL and
MIC90, 2 µg/mL). Vancomycin resistance increased significantly among enterococci during the study period, but it
was restrict to only one medical center until 2007 and emerged in a second medical center in 2008. Daptomycin was
the most active antimicrobial tested against enterococci in general (100.0% susceptible), followed by linezolid
(99.9% susceptible), ampicillin (87.4%) and vancomycin (84.6%). In conclusion, daptomycin and linezolid showed
excellent in vitro activity against contemporary Gram-positive organisms (3,907) collected in Brazilian hospitals
monitored by the SENTRY Program, including MRSA, vancomycin-resistant enterococci (VRE) and other multidrug-
resistant organisms. Although vancomycin resistance rates in Brazil appears to be relatively low compared to those
reported in the USA, VRE has emerged and rapidly disseminated in some Brazilian medical centers.
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Among the Gram-positive bacteria, staphylococci,
streptococci and enterococci are important causes of both
community- and hospital-acquired infections. Staphylococcus
aureus is particularly important as a frequent cause of sepsis
and many other types of nosocomial-acquired infections. This
organism represents the first or second most frequently
isolated pathogen from bloodstream infections, skin and skin
structure infections (SSSI), and pneumonia in hospitalized
patients [1,2]. Although the prevalence of methicillin-resistant
S. aureus (MRSA) may vary significantly, it is usually high in
Brazilian hospitals, especially in intensive care units (ICU).
Furthermore, MRSA are usually resistant to most antimicrobial
agents available for clinical use [3,4].
Coagulase-negative staphylococci (CoNS) has being also
recognized as an important cause of nososcomial infections
and this organism is usually more resistant to antimicrobial
agents than S. aureus [5]; while Enterococcus spp., mainly E.
faecalis and E. faecium, are among the most frequently isolated
pathogens from nosocomial infections in the United States
(USA) [1]. Vancomycin-resistant enterococci (VRE) emerged
in the early 80’s in USA hospitals and rapidly disseminated
throughout the country [6]. More recently, the occurrence of
VRE is increasing in many European hospitals while data from
Latin American countries are still scarce [7]
The SENTRY Antimicrobial Surveillance Program was
designed to monitor antimicrobial resistance among various
types of infection [2,8,9]. The Program was initiated in early
1997 and today it includes more than 120 medical centers in
North America, South America, Europe, Asia, and Western
Pacific regions. Data generated by large multicenter programs
are of great importance especially in developing regions such
as Latin America, where extensive surveillance studies are
not routinely conducted. We report the antimicrobial
susceptibility of the most frequently isolated Gram-positive
cocci in the Brazilian hospitals that participated in the SENTRY
Program in the 2005-2008 period.
Material and Methods
In Brazil, four institutions participate in the SENTRY
Program: Hospital São Paulo / UNIFESP, São Paulo, SP (A.C.
Gales, A.C. Pignatari and S. Andrade), Hospital de Clínicas de
Porto Alegre, Porto Alegre, RS (A. Barth), Hospital de Base
do Distrito Federal, Brasília, DF (J. Ribeiro) and Laboratório
Médico Santa Luzia, Florianópolis, SC (C. Zoccoli) which
collects bacterial isolates from 4 regional smaller public and/
or private hospitals (40 to 240 beds).
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Each institution collects approximately 500 consecutive,
non-duplicate bacterial isolates every year. All isolates are
identified at the participating institution by routine
methodologies in use at each laboratory. Upon receipt at the
central monitor (JMI Laboratories, North Liberty, IA, USA),
isolates were subcultured to ensure viability and purity.
Confirmation of species identification was performed with the
Vitek system (bioMérieux Vitek, St Louis, MO) or conventional
methods, as required.
A total of 3,907 Gram-positive bacteria collected between
January 2005 and September 2008, were analyzed in the present
study. The organisms were consecutively collected according
to the type of infections, which included mainly bloodstream
infections (57% of strains), skin and skin structure infections
(17%) and pneumonia in hospitalized patients (10%). The
Gram-negative organisms were analyzed separately and results
reported in another publication [9]. The organism collection
evaluated in this study included S. aureus (2,218 strains),
CoNS (812 strains), Enterococcus spp. (754 strains), β-
haemolytic streptococci (99 strains) and viridians group
streptococci (24 strains).
Antimicrobial susceptibility testing was performed by the
broth microdilution method, following recommendations of
the Clinical and Laboratory Standards Institute [10].
Antimicrobial powders were obtained from the respective
manufacturers and microdilution plates were prepared by
TREK Diagnostics (Cleveland, OH, USA). Susceptibility
results were interpreted according to CLSI document M100-
S18 [11]. Quality control was performed by testing S. aureus
ATCC 29213, E. faecalis ATCC 29212 and Streptococcus
pneumoniae ATCC 49619.
Results
Approximately 60% of isolates evaluated in the present
study were from bloodstream infections and the frequency of
occurrence of organisms isolated from this type of infection
is summarized in Figure 1. S. aureus (20.2% of total) was the
most common cause of bloodstream infection, followed by
CoNS (14.5%). Enterococcus spp. ranked 8th and was isolated
from 5.0% of bloodstream infection cases. S. aureus was also
the most common cause of SSSI (28.1%; Figure 2) and was
isolated from 24.9% of patients with pneumonia (Figure 3).
Enterococcus spp. was responsible for 4.5% of SSSI cases
(Figure 2).
In general, 31.0% of S. aureus strains were resistant to
oxacillin (MRSA) and the vast majority of MRSA strains were
also resistant to clindamycin, ciprofloxacin and levofloxacin
(Table 1). Furthermore, 68.1% of MRSA strains were resistant
to trimethoprim/sulfamethoxazole. Daptomycin and
vancomycin were active against all S. aureus strains tested
(100.0% susceptible). Linezolid was also very active against
S. aureus with only one strain being non-susceptible (MIC, 8
µg/mL) to this antimicrobial. Daptomycin (MIC50, 0.25 µg/mL
and MIC90, 0.5 µg/mL) was four- to eight-fold more potent
than vancomycin (MIC50 and MIC90 of 1 µg/mL) and linezolid
Figure 1. Frequency of occurrence of pathogens causing
bloodstream infections in Brazilian hospitals (3,807 strains;
2005-2008).
Figure 2. Frequency of occurrence of pathogens causing skin
and soft tissue infections in Brazilian hospitals (605 strains;
2005-2008).
Figure 3. Frequency of occurrence of pathogens isolated from
patients hospitalized with pneumonia in Brazilian hospitals
(875 strains; 2005-2008).
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Table 1. Antimicrobial susceptibility of staphylococci isolated in Brazilian hospitals (2005-2008).
Organism (no. tested)/    MIC (µg/mL) % susceptiblea % resistanta
Antimicrobial agent 50% 90%
MSSA (1,531)
Erythromycin ≤0.25 >2 86.2 13.0
Clindamycin ≤0.25 ≤0.25 98.1 1.7
Ciprofloxacin 0.25 0.5 95.2 2.2
Levofloxacin ≤0.5 ≤0.5 97.8 2.0
Tetracycline ≤2 >8 83.9 14.5
TMP/SMXc ≤0.5 ≤0.5 98.6 1.4
Linezolid 2 2 100.0 -b
Vancomycin 1 1 100.0 0.0
Daptomycin 0.25 0.5 100.0 -
MRSA (687)
Erythromycin >2 >2 6.0 94.0
Clindamycin >2 >2 11.2 87.9
Ciprofloxacin >4 >4 7.6 91.4
Levofloxacin 4 >4 8.6 90.2
Tetracycline ≤2 >8 52.8 46.7
TMP/SMXc >2 >2 31.9 68.1
Linezolid 1 2 99.9 -
Vancomycin 1 1 100.0 0.0
Daptomycin 0.5 0.5 100.0 -
All S. aureus (2,218)
Oxacillin 0.5 >2 69.0 31.0
Erythromycin ≤0.25 >2 61.3 38.1
Clindamycin ≤0.25 >2 70.7 28.4
Ciprofloxacin 0.5 >4 68.1 29.9
Levofloxacin ≤0.5 >4 70.2 29.3
Tetracycline ≤2 >8 74.3 24.5
TMP/SMXc ≤0.5 >2 77.9 22.1
Linezolid 1 2 >99.9 -
Vancomycin 1 1 100.0 0.0
Daptomycin 0.25 0.5 100.0 -
CoNS (812)
Oxacillin >2 >2 21.3 78.7
Erythromycin >2 >2 35.4 69.3
Clindamycin >2 >2 47.4 50.9
Ciprofloxacin 4 >4 42.2 55.7
Levofloxacin 2 >4 43.5 46.0
Tetracycline ≤2 >8 82.8 16.0
TMP/SMXc 2 >2 50.3 49.7
Linezolid 1 1 99.8 -
Vancomycin 1 2 100.0 0.0
Daptomycin 0.25 0.5 99.8 -
a. According to CLSI breakpoints [11]; b. - = no breakpoint has been established by the CLSI or USA-FDA; c. TMP/SMX = trimethoprim/
sulfamethoxazole.
(MIC50, 1 µg/mL and MIC90, 2 µg/mL) when tested against S.
aureus (Table 1).
Almost 80% of CoNS strains were resistant to oxacillin.
This organism showed high rates of resistance to most
antimicrobial agents tested (Table 1). Vancomycin (MIC50, 1
µg/mL and MIC90, 2 µg/mL) was active against all CoNS strain
at the susceptible breakpoint while two strains (0.2%) showed
decreased susceptibility to daptomycin (MIC of 2 µg/mL, one
doubling dilution above the susceptible breakpoint) and two
other strains showed high level of resistance to linezolid (MIC,
>8 µg/mL).
Approximately 83% of enterococci were E. faecalis and
7.7% showed vancomycin resistance (Table 2). Daptomycin
(MIC50 and MIC90 of 1 µg/mL) was active against all E. faecalis
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strains (100.0% susceptible) while linezolid (MIC50, 1 µg/mL
and MIC90, 2 µg/mL) was active against 99.8%, ampicillin
(MIC50, ≤ 1 µg/mL and MIC90, 4 µg/mL) was active against
98.9% and teicoplanin (MIC50 and MIC90 of ≤ 2 µg/mL)
inhibited 92.3% of strains at the susceptible breakpoint.
Vancomycin resistance increased from 4.4% in 2005 to
12.2% in 2008 among E. faecalis and 94% of vancomycin-
resistant strains (46 of 49) were isolated in one medical center.
On this particular medical center, vancomycin resistance
increased from 30.4% in 2005 to 50.0% in 2008 among E.
faecalis. All vancomycin-resistant E. faecalis strains were
susceptible to daptomycin and linezolid, and 95.9% were
susceptible to ampicillin. Daptomycin was the most potent
agent tested against vancomycin-resistant E. faecalis (MIC50
and MIC90 of 1 µg/mL; Table 2).
Among E. faecium strains, 65.7% of strains were resistant
to vancomycin (Table 2). Again, the vast majority of
vancomycin-resistant strains (47 of 59; 80%) were from one
medical center. Vancomycin-resistant E. faecium was not
observed in any medical center in 2005 and in only one medical
center in 2006 (at a rate of 74.2%) and 2007 (68.4%). In 2008
vancomycin-resistant E. faecium emerged in a second medical
center and both medical centers had high rates of vancomycin-
resistance among E. faecium strains (64.7 and 78.6%; data not
shown). Only daptomycin was active against all vancomycin-
resistant strains. Linezolid was also very active against
vancomycin-resistant E. faecium (98.5% susceptible), while
quinupristin/dalfopristin was active against 92.5% of strains.
Although high-level streptomycin resistance was observed
in 94.0% of vancomycin-resistant E. faecium strains, only 9.0%
showed high-level resistance to gentamicin. In contrast,
streptomycin resistance was observed in 16.3% of
vancomycin-resistant E. faecalis strains, while 63.5% of these
strains showed high-level resistance to gentamicin (Table 2).
When all enterococci strains are analyzed together,
daptomycin was the most active antimicrobial (100.0%
susceptible), followed by linezolid (99.9% susceptible),
ampicillin (87.4%) and vancomycin (84.6%). Although
ampicillin and vancomycin showed reasonable activity against
enterococci in general (84.6%-87.4% susceptible), these
compounds showed limited activity against E. faecium (15.7
and 34.3% susceptible respectively; Table 2).
Among viridans group streptococci, 87.5 and 91.7% were
susceptible to penicillin and ceftriaxone respectively, while
daptomycin (MIC50, 0.12 µg/mL and MIC90, 0.5 µg/mL),
levofloxacin (MIC50, ≤ 0.5 µg/mL and MIC90, 1 µg/mL), linezolid
(MIC50 and MIC90 of 1 µg/mL) and vancomycin (MIC50 and
MIC90 of 0.5 µg/mL) were active against all strains tested (100%
susceptible; Table 3). β-haemolytic streptococci exhibited high
rates of susceptibility to all antimicrobial agents tested, except
tetracycline (27.3% susceptible) and erythromycin (92.3%
susceptible; Table 3).
Table 4 shows the comparison of the in vitro potency of
the most active compounds, vancomycin linezolid and
daptomycin, tested against staphylococci and enterococci.
Daptomycin was generally four-fold more potent than linezolid
and vancomycin against staphylococci (S. aureus and CoNS).
All S. aureus and 99.8% of CoNS were inhibited at daptomycin
MIC of 1 µg/mL or less. Daptomycin and linezolid showed
similar in vitro activity against enterococci while vancomycin
exhibited more limited in vitro activity against this organism,
especially E. faecium (only 34.3% susceptible). MRSA strains
exhibited daptomycin MIC values slightly higher (MIC50, 0.5
µg/mL) than MSSA strains (MIC50, 0.25 µg/mL; Table 5). In
contrast, vancomycin-susceptible and -resistant enterococci
showed similar susceptibility to vancomycin (Table 5). CoNS
(MIC50, 0.25 µg/mL), as well as viridans group and β-haemolytic
streptococci (MIC50, ≤ 0.12 µg/mL) showed very low
daptomycin MIC values (Table 5).
Discussion
The high prevalence of MRSA in some Brazilian hospitals
is a concern because these isolates are often resistant to
multiple antimicrobial agents. The overall MRSA rate in the
present study was 31.0%, which is comparable to that reported
in previous studies [2]. However, MRSA rates may vary greatly
among hospitals or even among units of a hospital. The
emergence of MRSA is largely due to dissemination of clonal
strains, and temporary hospital outbreaks are typically due to
cross-transmission between patients of these strains.
Furthermore, a direct correlation between antimicrobial usage
and resistant rates has been difficult to establish due to a
high number of variables involved [12,13].
Vancomycin-resistant S. aureus (VRSA) is a serious
concern, but only very few isolates have been reported, all
from the USA and most of them from the state of Michigan. In
contrast, there are many reports of vancomycin-intermediate
S. aureus (VISA), especially after the reduction of the CLSI
vancomycin-susceptible breakpoint from 4 to 2 µg/mL [14].
Interestingly, we did not observe any S. aureus isolate with a
vancomycin-intermediate MIC value (4 µg/mL) in the present
study.
Another interesting finding of this study was the
documented linezolid resistance (one strain with MIC of 8 µg/
mL) and quinupristin/dalfopristin resistance (two strains with
MIC of 2 µg/mL [intermediate] and one strain with MIC >2 µg/
mL) among S. aureus. Although linezolid-resistant S. aureus
has been previously reported from Brazil [15], it remains
extremely rare in the Brazilian hospitals monitored by the
SENTRY Program. Acquired quinupristin/dalfopristin
resistance was reported in E. faecium from Brazilian hospitals
before this antimicrobial became available for clinical use in
this country [16]. The emergence and dissemination of this
resistance phenotype may be related to the clinical use of
natural streptogramin mixtures such as pristiniamycin and
synergistin, orally and topically since the 1960s.
S. aureus was the most common Gram-positive organism
recovered from bloodstream infections (20.2% of cases) and
SSSI (28.1%), and the second most common from patients
with pneumonia (24.9%). Furthermore, 31.0% of strains were
Antimicrobial Susceptibility of Gram-Positive Bacteria in Brazil (2005-2008)
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Table 2. Antimicrobial susceptibility of enterococci isolated in Brazilian hospitals (2005-2008).
Organism (no. tested)/   MIC (µg/mL) % susceptiblea % resistanta
Antimicrobial agent 50% 90%
E. faecalis
Vancomycin-susceptible. (576)
Ampicillin ≤1 4 99.1 0.0
Levofloxacin 1 >4 67.4 31.6
Gentamicin (HL)c ≤500 >100 74.3 25.7
Streptomycin (HL) ≤1000 >200 74.0 26.0
Linezolid 1 2 99.8 0.2
Teicoplanin ≤2 ≤2 100.0 0.0
Daptomycin 1 1 100.0 -b
Vancomycin-resistant (49)
Ampicillin 2 8 95.9 4.1
Levofloxacin >4 >4 4.1 95.9
Gentamicin (HL) >1000 >1000 26.5 63.5
Streptomycin (HL) ≤1000 >2000 83.7 16.3
Linezolid 1 2 100.0 0.0
Teicoplanin >16 >16 2.0 98.0
Daptomycin 0.5 1 100.0 -
All E. faecalis (625)
Ampicillin ≤1 4 98.9 1.1
Levofloxacin 1 >4 62.4 36.6
Gentamicin (HL) ≤500 >1000 70.6 29.4
Streptomycin (HL) ≤1000 >2000 74.7 25.3
Linezolid 1 2 99.8 0.2
Teicoplanin ≤2 ≤2 92.3 7.7
Vancomycin 2 2 92.2 7.7
Daptomycin 1 1 100.0 -
E. faecium
Vancomycin-susc. (35)
Ampicillin >16 >16 45.7 52.3
Levofloxacin 4 >4 48.6 42.9
Gentamicin (HL) ≤500 >1000 82.9 17.1
Streptomycin (HL) ≤1000 >2000 54.3 45.7
Quinupristin/dalfopristin 1 >2 57.1 20.0
Linezolid 1 2 100.0 0.0
Teicoplanin ≤2 ≤2 100.0 0.0
Daptomycin 2 4 100.0 -
Vancomycin-resistant (67)
Ampicillin >16 >16 0.0 100.0
Levofloxacin >4 >4 0.0 98.5
Gentamicin (HL) ≤500 ≤500 91.0 9.0
Streptomycin (HL) >2000 >2000 6.0 94.0
Quinupristin/dalfopristin 1 1 92.5 3.0
Linezolid 1 2 98.5 1.5
Teicoplanin >16 >16 0.0 98.5
Daptomycin 2 2 100.0 -0
All E. faecium (102)
Ampicillin >16 >16 15.7 84.3
Levofloxacin >4 >4 16.7 79.4
Gentamicin (HL) ≤500 >1000 88.2 11.8
Streptomycin (HL) >1000 >1000 22.6 77.4
Antimicrobial Susceptibility of Gram-Positive Bacteria in Brazil (2005-2008)
www.bjid.com.br
BJID 2009; 13 (April) 9 5
Quinupristin/dalfopristin 1 2 80.4 8.8
Linezolid 1 2 99.0 1.0
Teicoplanin >16 >16 34.3 64.7
Vancomycin >16 >16 34.3 65.7
Daptomycin 2 2 100.0 -
All enterococci (754)d
Ampicillin ≤1 >16 87.4 12.6
Levofloxacin 2 >4 56.6 41.9
Gentamicin (HL) ≤500 >1000 73.3 26.7
Streptomycin (HL) ≤1000 >2000 67.9 32.1
Quinupristin/dalfopristin >2 >2 12.3 80.8
Linezolid 1 2 99.9 0.1
Teicoplanin ≤2 >16 84.6 15.3
Vancomycin 2 >16 84.3 15.4
Daptomycin 1 1 100.0 -
a. According to CLSI breakpoints [11]; b.- = no breakpoint has been established by the CLSI or USA-FDA; c. HL = high level resistance; d. Includes
E. faecalis (625), E. faecium (102), E. avium (9), E. gallinarum (4), E. hirae (2), E. durans (1) and Enterococcus spp. (11).
Table 3. Antimicrobial susceptibility of streptococci isolated in Brazilian hospitals (2005-2008).
Organism (no. tested)/   MIC (µg/mL) % susceptible % resistant
Antimicrobial agent 50% 90%
Viridans group streptococci (24)
Penicillin 0.03 0.25 87.5 4.2
Ceftriaxone ≤0.25 0.5 91.7 8.3
Erythromycin ≤0.25 2 62.5 37.5
Clindamycin ≤0.25 ≤0.25 95.8 4.2
Levofloxacin ≤0.5 1 100.0 0.0
Tetracycline ≤2 >8 83.3 16.7
Linezolid 1 1 100.0 -b
Vancomycin 0.5 0.5 100.0 0.0
Daptomycin 0.12 0.5 100.0 -
β-haemolytic streptococci (99)
Penicillin 0.03 0.06 100.0 0.0
Ceftriaxone 0.25 0.25 100.0 0.0
Erythromycin ≤0.25 ≤0.25 92.9 7.1
Clindamycin ≤0.25 ≤0.25 98.0 2.0
Levofloxacin ≤0.25 1 100.0 0.0
Tetracycline >8 >8 27.3 72.7
Trimethoprim/sulfa ≤0.5 =0.5 99.0 1.0
Linezolid 1 1 100.0 -
Vancomycin 0.5 0.5 100.0 0.0
Daptomycin 0.12 0.25 100.0 -
a. According to CLSI breakpoints [11]; b. - = no breakpoint has been established by the CLSI or USA-FDA.
resistant to oxacillin. This finding emphasizes the importance
of the inclusion of an anti-MRSA drug in the initial antimicrobial
regimen for these infections [18,19]. Three antimicrobial agents
exhibited excellent potency and spectrum against MRSA and
staphylococci in general: vancomycin, linezolid and
daptomycin (Table 1). Vancomycin has been the standard
antimicrobial therapy for serious MRSA infections since the
early 1980s, when MRSA emerged as a significant nosocomial
pathogen in the USA [20]. However, vancomycin has
demonstrated slower in vitro bactericidal activity and clinical
responses compared with antistaphylococcal beta-lactams. A
reduction of efficacy of vancomycin against vancomycin-
susceptible MRSA strains with elevated vancomycin MIC
values (1-2 µg/mL) has also been extensively reported [14].
Furthermore, poor clinical response may also be related to the
lack of bactericidal activity, which has been reported in
approximately 20% of MRSA strains [21-24].
Linezolid also showed excellent anti-staphylococci
spectrum, but this agent is predominantly bacteriostatic and
has not been recommended for the treatment of some serious
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Table 4. Comparison of the in vitro potency of the most active compounds tested against Gram-positive pathogens.
Organism (no. tested)/ No. of isolates (cumulative %) inhibited at MIC (µg/mL) of:
Antimicrobial agent ≤0.12 0.25 0.5 1 2 4 8 16 >a
S. aureus (2,218)
Vancomycin 1(0.1) 2(0.1) 293(13.4) 1,867(97.5) 55(100.0)
Linezolid 0(0.0) 1(0.1) 55(2.5) 1,133(53.6) 1,028(99.9) 0(99.9) 1(100.0) -b
Daptomycin 51(2.3) 1,403(65.6) 732(98.6) 32(100.0) -b
CoNS (812)
Vancomycin 1(0.1) 5(0.7) 66(8.9) 444(36.6) 290(99.3) 6(100.0)
Linezolid 3(0.4) 4(0.9) 209(26.6) 569(96.7) 25(99.8) 0(99.8) 0(99.8) -b 2(100.0)
Daptomycin 65(8.0) 432(61.2) 282(95.9) 31(99.8) 2(100.0) -b
Enterococcus spp. (754)
Vancomycin 0(0.0) 1(0.1) 38(5.2) 308(46.0) 283(83.6) 6(84.4) 2(84.6) 0(84.6) 116(100.0)
Linezolid 0(0.0) 0(0.0) 15(2.0) 411(56.5) 326(99.7) 0(99.7) 1(99.9) -b 1(100.0)
Daptomycin 6(0.8) 12(2.4) 305(42.8) 322(85.5) 100(98.8) 9(100.0) -b
a. Greater than the highest concentration tested for this compound; b. Concentration not tested for this compound.
Table 5. Antimicrobial activity of daptomycin tested against Gram-positive organisms collected in Brazilian hospitals.
Organism (no. tested)/ No. of isolates (cumulative %) inhibited at daptomycin MIC (µg/mL) of:
Antimicrobial agent ≤0.12 0.25 0.5 1 2 4
S. aureus (2,218) 51(2.3) 1403(65.6) 732 (98.6) 32 (100.0) - -
MSSA (1,531) 41(2.7) 1,211(81.8) 262(98.9) 17(100.0) - -
MRSA (687) 10(1.5) 192(29.4) 470(97.8) 15(100.0) - -
Enterococci spp. (754) 6(0.8) 12(2.4) 305(42.8) 322(855) 100(98.8) 9(100.0)
E. faecalis
Vancomycin-susceptible(576) 5(0.9) 7(2.1) 268(48.6) 261(93.9) 34(99.8) 1(100.0)
Vancomycin-resistant (49) 0(0.0) 4(8.6) 21(51.0) 21(93.9) 2(98.0) 1(100.0)
E. faecium
Vancomycin-susceptible. (35) 0(0.0) 0(0.0) 2(5.7) 5(20.0) 23(85.7) 5(100.0)
Vancomycin-resistant (67) 0(0.0) 0(0.0) 2(3.0) 29(46.3) 36(100.0) -
Coagulase-negative staphylococci (812) 65(8.0) 432 (61.2) 282(95.9) 31(99.8) 2(100.0) -
Viridans group streptococci (24) 14(58.3) 2(66.7) 7(95.9) 1(100.0) - -
β-haemolytic streptococci (99) 69(69.7) 27(97.0) 3(100.0) - - -
infections, especially those in immunosuppressed patients
[25]. Although the clinical importance of bactericidal activity
in the treatment of most infections remains controversial,
antimicrobial treatments that provide bactericidal therapy have
been demonstrated to be superior to bacteriostatic regimens
in the treatment of S. aureus bacteremia/sepsis and also in the
treatment of systemic infections in immunosuppressed
patients [26,27].
Although vancomycin resistance in enterococci is
definitely increasing in the Brazilian hospitals participating in
the SENTRY Program, the results of this and other studies
indicate that this increase is medical center specific and
probably related to clonal dissemination of resistant clones
[6,28,29]. In Brazil, acquired vancomycin resitance among
enterococci was initially reported in E. faecium. However, more
recently E. faecalis became the predominant vancomycin-
resistant Enterococcus species in Brazilian hospitals. The
clonality of VRE has been evaluated in medical center (048) in
a previously published study which found two predominant
clones among vancomycin-resistant E. faecalis and a greater
clonal variability among vancomycin-resistant E. faecium
isolated in the intensive care units of that hospital [30].
The prevalence of vancomycin-resistant E. faecalis has
increased continuously, but is essentially restrict to one
medical center (048). Regarding E. faecium, the results of
this study showed that the prevalence of infections caused
by E. faecium in general (vancomycin-susceptible or -
resistant) remained very low until vancomycin-resistant E.
faecium emerged. E. faecium represented only 1.7 and 5.3%
of enterococcal strains in medical centers where vancomycin-
resistant E. faecium was not observed, and only 3.6% in
center 101 in the 2005-2007 period (vancomycin-resistant E.
faecium emerged in 2008 in this medical center). In contrast,
E. faecium represented 35.5% of enterococcal strains
collected in medical center 048 in the period of this study
and 27.4% of enterococcal strains isolated in medical center
101 in 2008. In summary, the occurrence of E. faecium
infections increased drastically when vancomycin-resistant
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E. faecium emerged and the majority of E. faecium infections
are due to vancomycin-resistant strains.
Only two compounds showed acceptable activity against
enterococci, those being daptomycin and linezolid. Linezolid
had potent in vitro activity against vancomycin-resistant E.
faecalis and E. faecium, as well as good therapeutic efficacy
for VRE bacteremia in mice [25]. However, as previously
discussed, linezolid has some limitations due to its
predominantly bacteriostatic activity [25].
In general, daptomycin demonstrated excellent in vitro
activity against recent clinical isolates of Gram-positive
species (3,907 isolates). Daptomycin is a novel lipopeptide
with potent in vitro activity against Gram-positive cocci [31-
35]. Daptomycin has a unique mechanism of action and has
demonstrated a rapid bactericidal activity against a wide
spectrum of Gram-positive organisms, including multidrug-
resistant (MDR) strains of staphylococci, enterococci and
streptococci [36]. Furthermore, daptomycin monotherapy was
shown to be superior to vancomycin monotherapy in the
treatment of experimental endocarditis due to methicillin
(oxacillin)-resistant S. aureus (MRSA)[26]. This agent was
approved by the USA Food and Drug Administration (USA-
FDA) and by the European Medicine Agency for the treatment
of complicated SSSI using a dose of 4 mg/kg every 24 hours
and S. aureus bacteremia, including right-sided endocarditis,
at an increased dose of 6 mg/kg every 24 hours [31,37].
Although vancomycin resistance rates in Brazil appears to
be relatively low compared to those reported in the USA [7],
VRE has emerged and rapidly disseminated in some medical
centers. Furthermore, the results of the present study confirmed
previous reports by showing that daptomycin is active against
many MDR Gram-positive strains and that vancomycin
resistance does not significantly affect its in vitro activity.
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